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Abstract
Background: We sought to investigate right ventricular (RV) function with Doppler tissue
imaging (DTI) in human immunodeficiency virus (HIV)-infected patients receiving highly-
-active antiretroviral treatment, without any heart-related symptoms.
Methods: We studied 38 asymptomatic HIV patients (aged 44.5 ± 9.2 years, 22 of them men)
and 25 age-matched and sex-matched controls. All subjects underwent conventional and DTI
estimation of left ventricular (LV) systolic and diastolic function, measuring peak systolic and
diastolic myocardial velocities at the mitral annulus (Sm, Em, Am). Two-dimensional (2-D)
echocardiographic study of the right ventricle (RV) was performed from the four-chamber view, and
RV end-diastolic dimensions were measured. DTI recordings from the RV free wall at the tricuspid
annulus were used to determine systolic (SmRV) and diastolic function (EmRV and AmRV).
Results: HIV-infected patients compared to controls exhibited significantly lower peak systolic
velocities at the septal-SmIVS (7.9 ± 1.3 vs 9.1 ± 1.4 cm/s, p = 0.002) and lateral mitral
annulus — SmLAT (9.8 ± 1.7 vs 11.2 ± 1.3 cm/s, p = 0.025); no difference was observed
regarding conventional 2-D examination of LV systolic and diastolic function and DTI-
-derived Em and Am. No significant difference occurred between HIV patients and controls
regarding RV end-diastolic dimensions and pulmonary artery systolic pressure. However,
SmRV (13.8 ± 1.6 vs 14.9 ± 2.2 cm/s, p = 0.040), EmRV (11.6 ± 3 vs 13.5 ± 2.6 cm/s, p = 0.028)
and AmRV (10.9 ± 2.5 vs 13.8 ± 4 cm/s, p = 0.003) were significantly reduced in HIV
patients as compared to controls.
Conclusions: DTI unmasks subtle and otherwise undetectable abnormalities of the longitu-
dinal LV systolic function and both RV systolic and diastolic function, in asymptomatic HIV
patients receiving highly-active antiretroviral treatment. (Cardiol J 2010; 17, 6: 587–593)
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Introduction
Cardiac abnormalities have been reported in
a substantial proportion of patients infected with the
human immunodeficiency virus (HIV) and are asso-
ciated with increased morbidity and mortality [1–3].
Among them, left ventricular (LV) dysfunction
seems to be caused by a self-limiting myocarditis
that rarely progresses to overt LV failure, while
isolated right ventricular (RV) dysfunction may be
either transient, as in cases of acute respiratory
infection and parenteral drug use, or permanent, in
the late disease complicated with pulmonary hyper-
tension [4–7].
However, most studies have been undertaken
before the era of highly-active antiretroviral treat-
ment (HAART), which has significantly reduced
HIV-associated morbidity and mortality rates [8].
Accordingly, few studies have screened for sub-cli-
nical cardiac abnormalities in HIV-infected patients
with well-controlled viral and immune status, pro-
viding contradictory data. Assessment of cardiac
function through radionuclide ventriculography has
exhibited rare left-sided impairment but a signifi-
cant reduction in RV ejection fraction [9]. In con-
trast, evaluation of cardiac function using conven-
tional echocardiography and novel techniques, in-
cluding Doppler tissue imaging (DTI), revealed
subtle systolic and consistent diastolic impairment
regarding LV, whereas RV parameters, except for
the arterial pulmonary pressure, were not affected
[10–12]. Taking into account that DTI estimates
contractility in the longitudinal axis and reveals
abnormalities earlier when compared to conventio-
nal echocardiography, we assessed RV function with
DTI in HIV-infected patients receiving HAART
without any heart-related symptoms.
Methods
Study design
Our study population consisted of 38 patients
(aged 44.5 ± 9.2 years, range 23–57, 30 of them
men) with positive HIV serology and absence of any
heart-related symptoms. The mean time from the
diagnosis of HIV infection was 54 ± 30 months.
Among them, 12 were in clinical stage A, 14 in clini-
cal stage B and 12 in clinical stage C, according to
the CDC criteria [13]. All patients included were
receiving HAART, including two nucleoside ana-
logues as backbone plus either a non-nucleoside
analogue and/or a protease inhibitor. Antibody lev-
els against HIV were measured by an enzyme linked
immunosorbent assay and confirmed by western
blot analysis. HIV-RNA was fully suppressed in
30 patients. CD4+ cell counts were determined
within three days of the echocardiographic study
(Facscan flow cytometer, Becton Dickinson, San
Jose, California, USA). Furthermore, 25 apparent-
ly healthy, age-matched and sex-matched individu-
als (aged 43 ± 9.7 years, range 22–56, 19 of them
men) with negative HIV serology were enrolled as
control subjects.
Patients with ischemic, hypertrophic, congeni-
tal or rheumatic cardiomyopathy, ethanol abuse
(> 90 g/day), diabetes mellitus, significant valvular
disease, and those with grade 2 and 3 hypertension
according to the European Society of Hypertension/
/European Society of Cardiology guidelines were
excluded from the study [14]. Moreover, HIV pa-
tients requiring antihypertensive and/or lipid lo-
wering medications were also excluded. The ethics
committee of our institution approved the study and
all patients gave written informed consent.
Echocardiographic methods
Standard transthoracic examination. Con-
ventional echocardiographic examination was per-
formed with a commercially available imaging sys-
tem (SSA-380A Toshiba Powervision, Japan) using
a 2.5-MHz phased array transducer employing se-
cond harmonic imaging by a single experienced
operator, who was unaware of the subjects’ subgroup.
Two-dimensional (2-D) guided M-mode measure-
ments of LV and left atrial dimensions were ob-
tained in the parasternal long-axis view according
to current guidelines [15]. LV mass was calculated
according to Devereux et al. [16] and normalized
for body surface area to obtain LV mass index [17].
Relative wall thickness was calculated at end dia-
stole according to the following equation: (interven-
tricular septum thickness + posterior wall thick-
ness)/(LV end-diastolic diameter). LV ejection frac-
tion was assessed using the biplane Simpson’s
method using conventional apical four- and two-
-chamber views. LV diastolic function was deter-
mined using conventional Doppler parameters
(peak velocities of E and A waves of the transmi-
tral flow, E/A ratio, isovolumic relaxation time and
the deceleration time of the E wave).
Pulsed-wave Doppler tissue imaging. Af-
ter establishing the resting baseline measurements,
a pulse wave DTI study was carried out, as previo-
usly described [11, 18]. From the apical four-cham-
ber view, a 5 mm pulsed Doppler sample volume
for DTI was positioned just apical to the septal and
lateral mitral annulus. Every effort was made to
obtain a Doppler angle of incidence close to zero
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degrees between the interrogating Doppler beam
and the longitudinal motion of the LV, to adjust the
sample volume size proportionally to annular mo-
tion and to obtain recordings at end-expiratory ap-
nea. The peak systolic myocardial velocities at the
septal (SmIVS) and lateral (SmLAT) mitral annulus, as
well as the peak early and late diastolic velocities
(EmIVS-EmLAT and AmIVS-AmLAT respectively), and
the ratios Emax/EmIVS and Emax/EmLAT were cal-
culated. The value assigned to each parameter was
the average of five cycles.
Right ventricular examination. The 2-D
echocardiographic study of the RV was performed
from the four-chamber view, and the following pa-
rameters were measured at end-diastole: tricuspid
annular diameter was measured between the hinge
points of the leaflets with the lateral wall and the
septum. Longitudinal RV diameter was measured
from the midpoint of tricuspid annular diameter to
RV apex. Mid-cavity diameter was also measured
at the four-chamber view [15, 19]. DTI recordings
from the RV free wall at the tricuspid level were
used to determine local systolic (SmRV) and diasto-
lic function (EmRV and AmRV). Tricuspid regurgita-
tion velocity was measured using continuous-wave
Doppler. Pulmonary artery systolic pressure was
determined using the modified Bernoulli equation
(P = 4 × V2 + right atrial pressure). The use of
the inferior vena cava size and dynamics was ap-
plied for estimation of the right atrial pressure [15].
Statistical analysis
SPSS statistical package, release 15.0 (SPSS
Inc., Chicago, Illinois, USA) was used for all statis-
tical analyses. Normality was tested using the Kol-
mogorov-Smirnov criterion. Logarithmic transfor-
mation was performed for skewed distributions
before any parametric analysis. Significant differ-
ences between the study sub-groups were deter-
mined using the Student independent-samples test
or the c2 test, where appropriate. Analysis of cova-
riance (ANCOVA) was performed in order to elimi-
nate any influence of age and body mass index on
detected differences between HIV-infected subjects
and controls. Correlation analyses were performed
using the Pearson’s correlation coefficient. Descrip-
tive statistics were arithmetic means ± standard
deviation or medians (interquartile range) for skewed
data. Statistical significance was set at p < 0.05.
Results
The clinical characteristics of our study popu-
lation are summarized in Table 1 and the results of
the echocardiographic indices are presented in
Tables 2–4 and Figures 1 and 2.
Left ventricular function
As regards LV function, conventional 2-D
echocardiographic examination did not show any
difference for all the variables studied between
groups (Table 2). Indeed, no difference was found
between HIV-infected patients and control indivi-
duals concerning the systolic performance (p = 0.49),
the LV end-systolic (p = 0.31) and end-diastolic
(p = 0.82) dimensions, as well as LV mass index
(p = 0.50) and relative wall thickness (p = 0.14). Simi-
larly, conventional Doppler study did not reveal any
differences in the diastolic function of HIV-infected
patients and controls, including LV relaxation (i.e. iso-
volumic relaxation time, p = 0.82), and LV filling (de-
celeration time, Emax, Amax, and Emax/Amax ratio).
Table 1. Clinical characteristics of the study population.
HIV (n = 38) Controls (n = 25) p
Age (years) 44.5 ± 9.2 43.3 ± 9.7 0.78
Males (%) 78 76 0.82
Body mass index [kg/m2] 25.0 ± 4.0 26.8 ± 3.7 0.11
Systolic blood pressure [mm Hg] 125.5 ± 12.0 124.3 ± 13.0 0.62
Diastolic blood pressure [mm Hg] 73.8 ± 9.0 72.0 ± 10.5 0.51
Heart rate [bpm] 80.1 ± 14.0 76.0 ± 13.0 0.25
CD4 count [cells/mL] 663 ± 236
Viral load [copies/mL] 66.7 ± 30
Nucleoside reverse transcriptase inhibitors (%) 100
Non-nucleoside reverse transcriptase inhibitors (%) 47.4
Protease inhibitors (%) 65.8
CD4 count — viral load levels and medication data are available only for HIV patients
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DTI study of the LV showed a significantly low-
er SmIVS (p = 0.002) and SmLAT (p = 0.025) at the
mitral annulus in HIV-infected patients compared
to controls, even after adjustment for age and body
mass index (Table 3). As far as diastolic function
was concerned, no differences were found between
HIV patients and controls in both lateral and septal
walls regarding peak Em (p = 0.87 and 0.94, respec-
tively) and Am velocities (p = 0.66 for the lateral
and 0.1 for the septal wall), as well as their ratios.
Moreover, both the Emax/EmLAT and the Emax/
/EmIVS ratios did not differ significantly between the
two study groups.
Right ventricular function
As far as RV was concerned, there was no dif-
ference between HIV patients and controls in RV
end-diastolic dimensions (Table 4). Notably, a trend
for higher pulmonary artery systolic pressure, even
though in the normal range, was observed in the HIV
subgroup 26.1 ± 3.8 vs 24.3 ± 3.2 mm Hg, p = 0.09.
Moreover, in HIV patients, peak systolic SmRV at
the RV free wall (p = 0.040) and both peak diasto-
lic EmRV (p = 0.028) and AmRV (p = 0.003) were sig-
nificantly reduced, even after adjustment for age
and body mass index. In addition, SmRV was posi-
Table 4: Comparison of right ventricular conven-
tional and Doppler tissue imaging echocardio-
graphic variables between the groups studied.
HIV Controls p
(n = 38)  (n = 25)
TAD [mm] 27.3 ± 4 27.2 ± 4 0.94
RVd 1 [mm] 29.5 ± 4.5 27.8 ± 4.2 0.15
RVd 2 [mm] 65.3 ± 8 68.8 ± 5.4 0.07
PASP [mm Hg] 26.1 ± 3.8 24.3 ± 3.2 0.09
SmRV [cm/s] 13.8 ± 1.6 14.9 ± 2.2 0.040
EmRV [cm/s] 11.6 ± 3 13.5 ± 2.6 0.028
AmRV [cm/s] 10.9 ± 2.5 13.8 ± 4 0.003
EmRV/AmRV 1.1 ± 0.32 1.1 ± 0.68 0.90
TAD — tricuspid annular diameter; RVd 1 — mid-cavity diameter;
RVd 2 — longitudinal diameter; PASP — pulmonary artery systolic
pressure; Sm — peak systolic myocardial velocity at the free right
ventricular (RV) wall; EmRV and AmRV — peak early diastolic and atrial
systolic velocity at the free RV wall as measured with Doppler tissue
imaging
Table 3. Comparison of left ventricular transmi-
tral and Doppler tissue imaging variables
between HIV patients and controls.
HIV Controls p
(n = 38)  (n = 25)
Emax [cm/s] 75.5 ± 14.0 72.7 ± 17.0 0.52
Amax [cm/s] 63.7 ± 13.0 61.0 ± 15.0 0.49
Emax/Amax 1.23 ± 0.34 1.27 ± 0.48 0.74
IVRT [ms] 87.7 ± 12.6 84.5 ± 14.2 0.82
DT [ms] 210 ± 44 195 ± 37 0.19
SmLAT [cm/s] 9.8 ± 1.7 11.2 ± 1.3 0.025
EmLAT [cm/s] 12.8 ± 4.0 13.0 ± 4.7 0.87
AmLAT [cm/s] 9.7 ± 2.8 9.4 ± 2.8 0.66
EmLAT/AmLAT 1.46 ± 0.75 1.55 ± 0.90 0.69
Emax/EmLAT 6.3 ± 1.7 5.9 ± 1.5 0.48
SmIVS [cm/s] 7.9 ± 1.3 9.1 ± 1.4 0.002
EmIVS [cm/s] 9.8 ± 2.3 9.7 ± 3.8 0.94
EmIVS [cm/s] 8.4 ± 2.0 9.3 ± 2.0 0.10
EmIVS/AmIVS 1.22 ± 0.40 1.11 ± 0.55 0.37
Emax/EmIVS 8.0 ± 1.9 8.0 ± 2.2 0.99
Emax and Amax — peak velocity of transmitral E and A waves; IVRT
— isovolumic relaxation time; DT — deceleration time; SmLAT/SmIVS —
peak systolic myocardial velocities at the left ventricular (LV) lateral and
septal wall, respectively; EmLAT/EmIVS and AmLAT/AmIVS — peak early
diastolic and atrial systolic velocity at the lateral and septal LV wall
Table 2. Comparison of left ventricular conventional echocardiographic variables between HIV patients
and controls.
HIV (n = 38) Controls (n = 25) p
Fractional shortening (%) 37.0 ± 5.5 37.0 ± 4.5 0.56
Ejection fraction (%) 66 ± 5 65 ± 7 0.49
LV end diastolic diameter [mm] 48.8 ± 4.6 47.5 ± 4.9 0.31
LV end systolic diameter [mm] 30.0 ± 3.9 29.8 ± 4.2 0.82
IVS [mm] 8.6 ± 1.7 9.1 ± 1.4 0.22
Posterior wall [mm] 8.8 ± 1.4 8.8 ± 1.0 0.99
Relative wall thickness 0.35 ± 0.05 0.38 ± 0.05 0.14
LV mass [g] 157.0 ± 46.0 154.5 ± 36.0 0.82
LV mass index [g/m2] 82.9 ± 19.0 79.6 ± 16.6 0.50
Left atrial diameter [mm] 37.7 ± 4.4 35.9 ± 5.4 0.19
LV — left ventricular; IVS — interventricular septum thickness
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tively correlated with SmIVS (r = 0.496, p < 0.001)
and negatively with age (r = –0.294, p = 0.033).
Discussion
The main finding of the present study was that
in asymptomatic HIV patients receiving HAART,
compared with age- and sex-matched control sub-
jects, DTI unmasked subtle (and undetectable by
conventional echocardiography) abnormalities of
the longitudinal LV systolic function and both RV
systolic and diastolic function.
Evidence for the effects of HIV on the heart
and vasculature has come most often from studies
performed before the current era of HAART, in
which viremia was less adequately suppressed. The
incidence of LV systolic function in the pre-HAART
era varied from 10% to 40% due to the diverse de-
finitions used, as well as to the differences in the
disease stages of the patients studied [1, 11, 20].
Figure 1. Box plot of peak systolic myocardial velocity at the left ventricular septal (SmIVS) (A) and lateral (SmLAT) (B) wall.
Figure 2. Box plot of peak systolic myocardial velocity (SmRV) (A), peak early diastolic (EmRV) (B) and atrial systolic
(AmRV) (C) velocity at the free right ventricular wall.
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Shortly after the introduction of HAART, a decrease
in HIV-related heart disease was reported, suggest-
ing the beneficial effects of treatments on immu-
nologic status and the subsequent decrease in op-
portunistic infections and myocarditis [21]. In the
present study, we confirmed our previous findings
of subtle systolic function abnormalities in patients
on HAART, based on DTI measurements rather
than conventional echocardiography [11]. The ab-
sence of diastolic function abnormalities, either with
conventional echocardiography or DTI, in spite of
previous reports, may be attributed to differences
in the stage of the disease, patients’ age, sample
size, prevalence of arterial hypertension and meta-
bolic disorders in the populations studied [10, 12, 22].
In addition, as we have previously shown, it seems
likely that in asymptomatic HIV-infected patients,
longitudinal LV and RV contractile function abnor-
malities, not otherwise detectable with convention-
al echo, precede diastolic dysfunction [11].
As far as RV function is concerned, echocar-
diographic studies conducted before HAART demon-
strated the presence of either transient isolated
RV dilatation associated with acute respiratory in-
fection and parenteral drug use or pulmonary hy-
pertension in late disease stages [4, 7, 23]. More-
over, in a small study using magnetic resonance im-
aging, RV ejection fraction impairment was found
in one third of the patients when using standard cut-
off values [6]. Interestingly, when HIV patients with
suppressed viral status were examined using radio-
nuclide ventriculography, a significant proportion
(7%) of right-sided cardiac dysfunction, as measured
by RV ejection fraction, was observed in the ab-
sence of LV dysfunction [9]. However, when cine
magnetic resonance imaging was performed in
treated HIV patients with radionuclide ventriculo-
graphy-estimated RV systolic dysfunction, only
a minority of them turned out to have a marginally
reduced RV ejection fraction, in the setting of nor-
mal RV dimensions and mass [24].
In our investigation, DTI-derived peak systo-
lic and diastolic velocities at the RV free wall were
significantly reduced in HIV patients under HAART
compared to controls, indicating abnormal RV func-
tion, at least in the long-axis. DTI study has been
shown to be able to unmask subtle and otherwise
undetectable cardiac damage because it estimates
contractility in the longitudinal axis in contrast to
conventional echocardiographic study [25]. Notably,
systolic RV abnormalities were closely related with
LV ones, suggesting a common underlying pathology.
It is of interest that decreased RV diastolic veloci-
ties were found in HIV-infected patients in the con-
text of unaffected LV diastolic velocities and in the
absence of overt pulmonary hypertension. A possi-
ble explanation for the latter finding is that, even in
the context of normal range, a trend for higher sys-
tolic pulmonary artery pressure was found in HIV-
-infected patients (p = 0.09) compared to healthy
subjects. Thus, differences in the pulmonary artery
systolic pressures may have altered RV diastolic
function.
Cardiac pathological abnormalities in HIV dis-
ease are complex, and most probably multifactorial,
and have been attributed to a direct myocardial
effect of the virus (HIV infection of myocytes or
dendritic cells), opportunistic infections, neoplasms,
long-term cardiotoxic adverse effects of therapies,
autoimmunity and abnormalities in nutritional sta-
tus [3, 10, 26]. Mitochondrial toxicity of nucleoside
reverse-transcriptase inhibitors, largely described in
various tissues, including cardiomyocytes, is a pos-
sibility, while use of protease inhibitors has been
associated with diastolic abnormalities based exclu-
sively on transmitral flow parameters [27, 28]. How-
ever, frequent alterations in antiretroviral drug regi-
mens as well as the limited sample size did not al-
low the correlation of observed cardiac abnormalities
to different antiretroviral agents.
As cardiac involvement in HIV-infected pa-
tients affects negatively their prognosis (in terms
of both morbidity and mortality), an early recogni-
tion of either LV or RV dysfunction is crucial. In-
deed, even sub-clinical echocardiographic abnor-
malities independently predict adverse outcomes
and identify high-risk groups to target for early in-
tervention and therapy [2]. Under this point of view,
DTI may constitute a useful diagnostic tool for
asymptomatic HIV-infected patients, aimed at iden-
tifying precocious cardiac involvement and begin-
ning appropriate treatment. Particularly, in patients
revealing early cardiac function abnormalities with
DTI, treatment shifting towards less cardiotoxic
antiretroviral therapy should probably be consid-
ered. Moreover, early administration of therapy
targeting to reduce progression (or cause regres-
sion) of early cardiac dysfunction in HIV-infected
patients (and whether this approach translates into
improved survival) remains to be established from
prospective studies.
Limitations of the study
It is unclear whether cardiac abnormalities
detected with DTI are more a result of the infec-
tion itself or the consequence of the aggressive
treatment. Towards this direction assessment of
HIV treatment-naive patients would help us dis-
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criminate, at least partially, the pathogenic role of
HIV infection and treatment separately. Moreover,
the time from the diagnosis of HIV infection was
different for each patient. As a result, the time pe-
riod under therapy (or the period without therapy)
differs between them. It would be of interest to
study prospectively (with serial DTI studies) indi-
viduals with a recent exposure to HIV and assess
the parameters (and the relative depth of time)
which contribute to the longitudinal chambers func-
tion impairment. This is a limited size study and,
as a result, large scale investigations are required
to confirm our findings. However, even this sam-
ple size did not prevent us from identifying signifi-
cant differences between patients and controls, at
least for some of the parameters assessed. Further-
more, we have no data on acceleration time of pul-
monary flow waves which would significantly im-
prove assessment of pulmonary circulation.
Conclusions
DTI, but not conventional echocardiography,
reveals cardiac function abnormalities in asympto-
matic HIV patients, with well controlled viral and
immune status compared to age- and sex-matched
controls. Longitudinal RV systolic and diastolic dys-
function, although less frequently studied, seems
to be more prominent in this setting.
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